GEN-MKT-18-7897-A
Aug 20, 2015 | Blogs, Life Science Research, Proteomics | 0 comments
A recent study by Katy Williams (UCSF), Christie Hunter (SCIEX), and Andrew Olsen (Advaita) used the iPathwayGuide within the OneOmics cloud computing environment to help understand how placental development can go awry during certain pregnancy complications such as pre-eclampsia.
In this pilot study, the researchers studied cytotrophoblast differentiation. Cytotrophoblasts are the cells that are mainly responsible for establishing an anchor between the developing embryo and placenta with the uterine wall. The researchers compared cytotrophoblasts from the primary culture at both 2nd trimester and full term. SWATH proteomics data acquired using a SCIEX TripleTOF® 6600 System were analyzed in OneOmics using iPathwayGuide to identify differentially regulated proteins and their associated pathways, biological processes, and molecular functions. The proteomics data were then compared with RNASeq transcriptomics data acquired using an Illumina HiSeq System. Both the proteomics data and transcriptomics data were correlated using the OneOmics Platform and iPathwayGuide in the cloud. This meta-analysis allowed the researchers to discover common pathways and processes between the data sets as well as those only observed in the proteomic or transcriptomic datasets alone.
The pilot study helped to illuminate the biological significance of multiple proteins and pathways and provided an effective pipeline for taking raw data to biological answers.
See the complete study by viewing a 10 minute mini webinar. If you’d like to get a demo of the OneOmics Project, just comment below and we’ll be in touch.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network